Compare XMTR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | PBLS |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 2021 | 2026 |
| Metric | XMTR | PBLS |
|---|---|---|
| Price | $93.09 | $37.38 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $58.60 | N/A |
| AVG Volume (30 Days) | ★ 803.3K | 388.3K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $35.86 | $25.56 |
| 52 Week High | $106.08 | $36.95 |
| Indicator | XMTR | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 68.83 |
| Support Level | $88.52 | $26.42 |
| Resistance Level | $98.55 | N/A |
| Average True Range (ATR) | 4.67 | 2.30 |
| MACD | 0.33 | 0.31 |
| Stochastic Oscillator | 77.15 | 95.45 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.